Ipsen initiates a new share buy-back program to cover its free performance share allocation plan

This program is made pursuant to the authorization granted by the Combined Shareholder’s meeting held on May 31, 2016.

Understanding the true impact of living with FOP

Ipsen Announces Decision to Permanently Discontinue Distribution of NutropinAq® (somatropin) cartridges

Applications now open for the 2023 Golden Ticket Competition

Offering support to those impacted in Turkey & Syria

© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved - 2023